{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:20:48Z","timestamp":1788675648828,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T00:00:00Z","timestamp":1637884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T00:00:00Z","timestamp":1637884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s40265-021-01643-6","type":"journal-article","created":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T16:02:53Z","timestamp":1637942573000},"page":"79-85","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Avacopan: First Approval"],"prefix":"10.1007","volume":"82","author":[{"given":"Arnold","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,26]]},"reference":[{"key":"1643_CR1","unstructured":"ChemoCentryx. ChemoCentryx announces FDA approval of TAVNEOS\u2122 (avacopan) in ANCA-associated vasculitis [media release]. 8 Oct 2021. https:\/\/ir.chemocentryx.com\/."},{"issue":"1","key":"1643_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1\u201311.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"1643_CR3","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne DRW, Merkel PA, Schall TJ, et al. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384(7):599\u2013609.","journal-title":"N Engl J Med"},{"key":"1643_CR4","unstructured":"Kissei Pharmaceutical. Marketing Authorization Approval in Japan for TAVNEOS(Rm) capsules 10mg, a selective complement C5a receptor antagonist [media release]. 27 Sept 2021. http:\/\/www.kissei.co.jp."},{"key":"1643_CR5","unstructured":"ChemoCentryx. Avacopan (TAVNEOS): Japanese prescribing information. 2021. https:\/\/www.pmda.go.jp\/. Accessed 05 Nov 2021."},{"key":"1643_CR6","unstructured":"ChemoCentryx. Avacopan (TAVNEOS): US prescribing information. 2021. https:\/\/www.chemocentryx.com\/. Accessed 05 Nov 2021."},{"key":"1643_CR7","unstructured":"European Medicines Agency. First-in-class medicine recommended for treatment of rare blood vessel inflammation [media release]. 12 Nov 2021. https:\/\/www.ema.europa.eu\/.."},{"key":"1643_CR8","unstructured":"Vifor Pharma. Vifor Pharma reports strong H1 2021 growth, on track to meet full year guidance [media release]. 5 Aug 2021. http:\/\/viforpharma.com."},{"key":"1643_CR9","unstructured":"GlaxoSmithKline, ChemoCentryx Inc. GlaxoSmithKline and ChemoCentryx enter into drug discovery and development alliance in inflammatory disorders [media release]. 24 Aug 2006. http:\/\/www.gsk.com."},{"key":"1643_CR10","unstructured":"ChemoCentryx. ChemoCentryx announces positive top-line CCX168 phase II data in ANCA-associated renal vasculitis [media release]. 3 Dec 2013. https:\/\/ir.chemocentryx.com\/."},{"key":"1643_CR11","unstructured":"Galenica Group. Galenica 2016: further increase in sales and confirmation of profit forecasts [media release]. 19 Jan 2017. http:\/\/www.galenica.com."},{"key":"1643_CR12","unstructured":"Vifor Pharma. Vifor Pharma licenses rights to commercialize ChemoCentryxs orally-administered complement 5aR inhibitor CCX168 for orphan and rare renal diseases in Europe and certain other major markets [media release]. 10 May 2016. http:\/\/www.viforpharma.com."},{"key":"1643_CR13","unstructured":"Vifor Pharma. Vifor Pharma and ChemoCentryx announce expansion of avacopan agreement for rare renal diseases [media release]. 14 Feb 2017. http:\/\/viforpharma.com."},{"key":"1643_CR14","unstructured":"ChemoCentryx. ChemoCentryx reports second quarter 2018 financial results and recent highlights [media release]. 9 Aug 2018. https:\/\/ir.chemocentryx.com\/."},{"key":"1643_CR15","unstructured":"Vifor Fresenius Medical Care Renal Pharma. Kissei to market avacopan in Japan for Vifor Fresenius Medical Care Renal Pharma [media release]. 9 Jun 2017. http:\/\/viforpharma.com."},{"key":"1643_CR16","unstructured":"ChemoCentryx. Form 10-K annual report. 2021. https:\/\/ir.chemocentryx.com\/. Accessed 05 Nov 2021."},{"issue":"10","key":"1643_CR17","doi-asserted-by":"publisher","first-page":"e0164646","DOI":"10.1371\/journal.pone.0164646","volume":"11","author":"P Bekker","year":"2016","unstructured":"Bekker P, Dairaghi D, Seitz L, et al. Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized phase 1 clinical study. PLoS\u00a0One. 2016;11(10):e0164646.","journal-title":"PLoS\u00a0One"},{"issue":"2","key":"1643_CR18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2013020143","volume":"25","author":"H Xiao","year":"2014","unstructured":"Xiao H, Dairaghi DJ, Powers JP, et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol. 2014;25(2):225\u201331.","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 3","key":"1643_CR19","first-page":"iii381","volume":"30","author":"S Gastoldi","year":"2015","unstructured":"Gastoldi S, Charo IF, Dairaghi D, et al. Inhibition of the C5A receptor by CCX168 markedly reduces the thrombogenic potential of serum from patients with atypical hemolytic uremic syndrome [abstract no. SP004]. Nephrol Dial Transplant. 2015;30(Suppl 3):iii381\u201392.","journal-title":"Nephrol Dial Transplant"},{"key":"1643_CR20","unstructured":"US National Institutes of Health. ClinicalTrials.gov record for NCT02464891. 2017. https:\/\/clinicaltrials.gov\/. Accessed 05 Nov 2021."},{"issue":"21","key":"1643_CR21","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1056\/NEJMc2104672","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne DRW, Merkel PA, Bekker P. Avacopan for the treatment of ANCA-associated vasculitis. Reply. N Engl J Med. 2021;384(21):e81.","journal-title":"N Engl J Med"},{"issue":"11","key":"1643_CR22","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/acr2.11185","volume":"2","author":"PA Merkel","year":"2020","unstructured":"Merkel PA, Niles J, Jimenez R, et al. Adjunctive treatment with avacopan, an oral C5a receptor inhibitor, in patients with antineutrophil cytoplasmic antibody-associated vasculitis. ACR Open Rheumatol. 2020;2(11):662\u201371.","journal-title":"ACR Open Rheumatol."},{"issue":"9","key":"1643_CR23","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1681\/ASN.2016111179","volume":"28","author":"DRW Jayne","year":"2017","unstructured":"Jayne DRW, Bruchfeld AN, Harper L, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017;28(9):2756\u201367.","journal-title":"J Am Soc Nephrol"},{"key":"1643_CR24","unstructured":"Vifor Fresenius Medical Care Renal Pharma, ChemoCentryx Inc. VFMCRP and ChemoCentryx provide topline results from ACCOLADE trial of avacopan in C3 glomerulopathy including improved estimated glomerular filtration rate (eGFR) [media release]. 21 Dec 2020. http:\/\/viforpharma.com."},{"key":"1643_CR25","unstructured":"ChemoCentryx. ChemoCentryx announces positive topline results of phase II AURORA clinical trial of avacopan in the treatment of hidradenitis suppurativa (HS) [media release]. 28 Oct 2020. https:\/\/ir.chemocentryx.com\/."},{"issue":"3","key":"1643_CR26","first-page":"140","volume":"4","author":"A Bruchfeld","year":"2018","unstructured":"Bruchfeld A, Nachman PH, Parikh S, et al. C5A receptor inhibitor avacopan in IgA nephropathy\u2014a pilot study [abstract]. Kidney Dis. 2018;4(3):140\u20131.","journal-title":"Kidney Dis"},{"key":"1643_CR27","unstructured":"ChemoCentryx. Data on file. 2021"},{"key":"1643_CR28","unstructured":"ChemoCentryx. ChemoCentryx reports first quarter 2021 financial results and recent highlights [media release]. 29 Apr 2021. https:\/\/ir.chemocentryx.com\/."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01643-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01643-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01643-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T10:38:37Z","timestamp":1641811117000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01643-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,26]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1643"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01643-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,26]]},"assertion":[{"value":"26 November 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. A. Lee is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}